Cutter & CO Brokerage, Inc. Obs Eva Sa Transaction History

Cutter & CO Brokerage, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$0.08 - $0.23 $4,280 - $12,305	-53,500 Reduced 26.59%	147,700 $14,000
Q4 2022 Feb 03, 2023	BUY	$0.14 - $0.21 $392 - $588	2,800 Added 1.41%	201,200 $28,000
Q3 2022 Nov 03, 2022	SELL	$0.14 - $1.83 $672 - $8,784	-4,800 Reduced 2.36%	198,400 $28,000
Q2 2022 Jul 28, 2022	SELL	$1.34 - $2.08 $4,020 - $6,240	-3,000 Reduced 1.45%	203,200 $327,000
Q1 2022 May 03, 2022	BUY	$1.1 - $2.17 $31,075 - $61,302	28,250 Added 15.88%	206,200 $311,000
Q4 2021 Feb 10, 2022	BUY	$1.99 - $3.1 $51,740 - $80,600	26,000 Added 17.11%	177,950 $354,000
Q3 2021 Nov 02, 2021	BUY	$2.47 - $3.34 $18,278 - $24,716	7,400 Added 5.12%	151,950 $473,000
Q1 2021 May 11, 2021	BUY	$2.01 - $5.05 $12,059 - $30,300	6,000 Added 4.33%	144,550 $470,000
Q4 2020 Feb 03, 2021	BUY	$1.89 - $2.55 $241,920 - $326,400	128,000 Added 1213.27%	138,550 $288,000
Q3 2020 Nov 05, 2020	SELL	$2.46 - $6.15 $54,612 - $136,530	-22,200 Reduced 67.79%	10,550 $26,000
Q2 2020 Aug 10, 2020	BUY	$2.01 - $5.95 $65,827 - $194,862	32,750 New	32,750 $193,000

88K

Ticker OBSV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,499,200
Description
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...

Get notified when there are updates to the investment portfolio of Cutter & CO Brokerage, Inc., based on Form 13F filings with the SEC.

Stay updated on Cutter & CO Brokerage, Inc. with notifications on news.